Xilio Therapeutics, Inc. Profile Avatar - Palmy Investing

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Pha…

Biotechnology
US, Waltham [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of XLO's Analysis
CIK: 1840233 CUSIP: 98422T100 ISIN: US98422T1007 LEI: - UEI: -
Secondary Listings
XLO has no secondary listings inside our databases.